GILD — Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Product Sales: $28.9 billion for 2025, up 1% YoY, exceeding guidance of $28.4-$28.7 billion. Excluding Vecluri, sales were $28 billion, a 4% increase.
• Q4 Product Sales: $7.9 billion, a 5% increase YoY; $7.7 billion excluding Vecluri, up 7% YoY.
• HIV Business: Record sales of $20.8 billion for 2025, up 6% YoY, driven by Biktarvy and Descovy.
• Operating Margin: 45% for 2025, with a product gross margin of 86.4%.
• Non-GAAP EPS: $8.15, in line with guidance of $8.5-$8.25.
• Shareholder Returns: $5.9 billion returned, including $1.9 billion in share repurchases.

2. Strategic Updates and Business Highlights

• HIV Portfolio Growth: Biktarvy sales reached $14.3 billion, up 7% YoY. The new injectable HIV prevention drug, YES2GO, launched successfully with $150 million in sales for 2025 and is expected to reach $800 million in 2026.
• Liver Disease: Sales for liver treatments grew 6% YoY to $3.2 billion, driven by Libdelzi's adoption.
• Oncology: Trodelvy sales increased 6% YoY to $1.4 billion, with positive phase three trial results boosting demand.
• Pipeline Progress: Gilead has a robust pipeline with multiple upcoming launches and phase three updates expected in 2026, including Trodelvy in first-line metastatic breast cancer and Anidocel for multiple myeloma.

3. Forward Guidance and Outlook

• 2026 Guidance: Total product sales expected between $29.6 billion and $30 billion. Base business sales projected to grow 4-5% YoY.
• HIV Sales Growth: Anticipated at 6% for 2026, with YES2GO expected to contribute significantly.
• Cell Therapy Decline: Kite revenue expected to decline approximately 10% in 2026 due to competitive pressures.
• Operating Margin: Expected to remain strong, with continued focus on expense management.

4. Bad News, Challenges, or Points of Concern

• Vecluri Sales Decline: Revenue fell 49% YoY to $911 million due to reduced COVID-19 hospitalizations.
• Competitive Pressures: Cell therapy sales are facing ongoing competition, impacting revenue forecasts.
• Policy Headwinds: Anticipated 2% headwind to growth in 2026 due to drug pricing agreements and changes to the Affordable Care Act.
• Market Dynamics: Transitioning from oral to injectable therapies may present logistical challenges and slower adoption rates.

5. Notable Q&A Insights

• YES2GO Growth: Management expressed optimism about YES2GO's potential, highlighting strong payer coverage and a direct-to-consumer campaign to drive awareness. However, they acknowledged the need for careful navigation of logistics in a shift to injectables.
• Anidocel Market Entry: Confidence in a second-half 2026 launch was noted, with expectations of becoming a market leader due to its efficacy profile.
• Trodelvy Off-Label Use: There are indications of off-label use in first-line settings, supported by positive trial results and NCCN recommendations.
• Market Expansion: Discussions on the potential for new therapies, including a once-yearly injectable for HIV, were highlighted as significant opportunities for broadening patient access.

Overall, Gilead Sciences, Inc. reported solid financial performance in 2025, driven by strong growth in its HIV portfolio and promising pipeline developments. However, challenges related to competitive pressures and policy changes pose risks to future growth.